BioNTech Drug Nearly Doubles Survival in Hard-to-Treat Lung Cancer
Updated PRESERVE-003 data: gotistobart showed 18.5 vs 10 months median survival vs chemo in previously treated squamous NSCLC. Pivotal stage ongoing.
/ 12 items
#BNTX↓
BioNTech Stops Phase 2 Trial of Personalized mRNA Vaccine in High-Risk Colorectal Cancer
BioNTech terminated BNT122-01 after the DSMB found an OS imbalance and said continuing was unlikely to change the outcome.
From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
BioNTech Co-Founders Ugur Sahin and Özlem Türeci Launch New mRNA Biotech as Company Sharpens Focus on Cancer Pipeline
BioNTech co-founders Ugur Sahin & Özlem Türeci are starting an independent next-gen mRNA company by end-2026. BioNTech keeps focus on oncology (15 Phase 3 trials).
Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
Goldman Sachs Upgrades BioNTech to Buy, Sees Strong Cancer Therapy Potential
Goldman Sachs raises BioNTech to Buy, citing its strong position in oncology and upcoming 2026 data that could boost new cancer therapies.